JZ CAPITAL PARTNERS LIMITED
(a closed-end investment company incorporated with limited liability under the laws of Guernsey with registered number 48761)
Q1 2017 Interim Management Statement
29 June 2017
JZ Capital Partners Limited (LSE: JZCP.L, the “Company” or “JZCP”), the London listed fund that invests in US and European micro-cap companies and US real estate, today releases its Interim Management Statement for the period 1 March 2017 to 31 May 2017.
- Net Asset Value (“NAV”) of $833.3 million (28/02/17: $848.8 million)
- NAV per share of $9.93 (28/02/17: $10.12)
- $43.9 million invested during the period, including:
- $12.0 million invested in new co-investment Felix Storch
- $4.5 million follow-on investment in Jordan Health Products
- $1.2 million net investment in Reflective Apparel Factory (“RAF”), a Technical Services and Solutions (“TSS”) vertical add-on acquisition
- $16.3 million realised, including:
- $12.5 million from the first tranche of proceeds for Fidor Bank
- At the end of the period, the portfolio consisted of 34 micro-cap investments across nine industries and four major real estate “assemblages” (59 total properties) located in New York and South Florida
- In May 2017, JZCP received shareholder approval for certain initiatives designed to maximize shareholder returns, including the discontinuation of the Company’s current dividend policy and inception of a new strategy to allow for the repurchase of shares
- In April 2017, JZCP increased its loan facility with Guggenheim Partners from approximately $100 million to $150 million in order to provide additional liquidity to JZCP in order to bridge certain planned realisations. The entire $150 million facility may be repaid, in whole or in part, with no penalty after June 2017
David Zalaznick, Founder and Investment Advisor of JZCP said: “Despite the challenging market environment, the strength of our balance sheet has again allowed us to put money to work across the US and European micro-cap and US real estate sectors.
We continue to believe that the US market presents a number of potential realisation opportunities for the Company and we remain confident in the outlook for our diversified portfolio.”
Net Asset Value
NAV per share for the quarter decreased from $10.12 to $9.93, or 1.9%.
|Net Asset Value per Ordinary Share as of 1 March 2017||$10.12|
|Change in NAV per share due to capital gains and income received / accrued on investments|
|Other changes in NAV per share|
|Change in CULS Fair Value||(0.01)|
|Foreign Exchange Effect||0.08|
|Expenses and Taxation||(0.04)|
|Net Asset Value per Ordinary Share as of 31 May 2017||$9.93|
The US micro-cap portfolio had a net increase of 3 cents, primarily due to net accrued income of 5 cents and write-ups at our healthcare revenue cycle management vertical (2 cents) and logistics vertical (1 cent). Jordan Health Products was also written up 2 cents. An escrow payment related to our exited co-investment Medplast added 1 cent. Offsetting these uplifts in valuation were decreases in value at our legacy Nationwide Studios business (1 cent) and our ISS vertical (9 cents).
The European micro-cap portfolio had a net decrease of 5 cents, primarily due to 1cent of accrued income offset by a 6 cent write-down at Factor Energia.
The real estate portfolio had a net decrease of 6 cents, primarily due to estimates of debt service, operating costs and other expenses at the property level.
Finally, our other investments had a net decrease of 6 cents, primarily due to a write-down at Spruceview (6 cents).
The chart below summarises the cumulative total NAV returns and total shareholder returns for the most recent three-month, twelve-month, three-year and five-year period.
|Since 28/02/17||Since 31/05/16||Since 31/05/14||Since 31/05/12|
|Share price (in GBP)||£5.66||£5.38||£3.90||£4.41||£3.68|
|Dividends paid (in USD)||—||—||$0.16||$0.79||$1.57|
|Total Shareholders' return (GBP)1||—||5.2%||48.9%||45.3%||95.0%|
|NAV per share (in USD)||$9.93||$10.12||$10.32||$10.08||$9.38|
|NAV per share total returns1||—||(1.9)%||(2.3)%||6.5%||24.2%|
|NAV to market price discount||26%||34%||45%||27%||40%|
- Total returns are cumulative and assume that dividends were reinvested
Significant Investments and Realisations
US Micro-cap Investments – Verticals
TSS Vertical (formerly known as ‘testing’ vertical)
In May 2017, JZCP invested $1.2 million (investment net of proceeds from refinancing the entire testing vertical) to acquire RAF, which produces high-end reflective apparel purchased by transportation, municipal, construction and industrial customers.
US Micro-cap Investments – Co-investments
In March 2017, JZCP invested a further $4.5 million in Jordan Health Products, to fund the acquisition of Transtate, a business which sells, services, repairs and installs refurbished medical imaging equipment, specializing in catheter angiography equipment.
Also in March 2017, JZCP invested $12.0 million in Felix Storch, a business that manufactures and distributes specialty refrigeration products and appliances.
European Micro-cap Investments
In April and May 2017, JZCP made three short-term loans to EuroMicrocap Fund-B, L.P., totalling $5.4 million, to bridge investments in Docout, Ombuds and One World Packaging.
We expect these loans to be paid back before their stated maturity dates of 31 July 2017.
Real Estate Investments
In the three-month period ended 31 May 2017, JZCP invested a total of $10.4 million in follow-on investments in our Williamsburg Retail, Design District and Greenpoint properties.
JZCP sold its interest in Fidor Bank (“Fidor”) to Groupe BPCE, the second largest banking group in France. The transaction closed in December 2016. JZCP invested a total of $13.8 million and is expected to receive total gross proceeds of approximately $25 million from the sale. JZCP received its first tranche of proceeds totalling $12.5 million in March 2017.
At 31 May 2017, the Company’s portfolio consisted of 34 micro-cap investments across nine major industries and four major real estate “assemblages” (59 total properties) located in New York and South Florida.
|($’000)||At 31/05/17||At 28/02/17||% Gross Assets 31/05/17|
|US Micro-cap Portfolio||442,147||424,502||38.9%|
|European Micro-cap Portfolio||162,183||154,277||14.2%|
|Real Estate Portfolio||474,758||468,599||41.7%|
|Total Private Investments||1,094,932||1,069,180||96.2%|
|Total Investments (and Cash)||1,137,194||1,098,244||99.9%|
|Other Current Assets||596||511||0.1%|
|Total Investments (and Cash)||1,137,790||1,098,755||100.0%|
At 31 May 2017, 3.7% of gross assets were invested in “liquid” assets (cash). The remaining portion of the portfolio was invested in private investments in US or European micro-cap companies or real estate. These investments are valued at fair value by JZCP’s directors each quarter.
We value our privately held businesses carefully. Our average multiple used for our US micro-cap businesses is 8.2x trailing EBITDA. In addition, we do not have substantial debt in these businesses. The multiple of debt senior to JZCP’s position is approximately 3.4x EBITDA.
Top Ten Investments
Our ten largest investments as of 31 May 2017 are summarised below:
|($000’s)||Asset Category||Valuation 31/05/17||% Gross Assets
|Design District Assemblage||Real Estate||100,570||8.8%|
|Industrial Services Solutions Vertical||US||77,653||6.8%|
|Healthcare Rev. Cycle Management Vertical||US||70,273||6.2%|
|Williamsburg Retail||Real Estate||68,718||6.0%|
|Fulton Assemblage||Real Estate||62,011||5.5%|
|EuroMicrocap Fund-C, L.P.||European||61,077||5.4%|
|Jordan Health Products||US||37,354||3.3%|
|Top Ten Investments||636,438||55.9%|
Below is a summary of JZCP’s balance sheet as of the relevant dates:
|Cash and cash equivalents||42,262||29,064|
|Investments & other assets||1,095,528||1,069,691|
|(-) Other net liabilities||(247,780)||(195,976)|
|(-) ZDPs due 2022||(56,669)||(53,935)|
|Net Asset Value||833,341||848,844|
At 31 May 2017, “other net liabilities” includes $60.2 million from the issuance of Convertible Unsecured Loan Stock (“CULS”) in July 2014, which carries an interest rate of 6%, and $147.6 million from a six-year term loan with Guggenheim Partners, which carries an interest rate of LIBOR plus 5.75%.
For Further Information:
Ed Berry / Kit Dunford +44 (0) 20 3727 1046 / 1143
David Zalaznick +1 212 485 9410
Jordan/Zalaznick Advisers, Inc.
Teresa Le Couteur-Tembo +44 (0) 1481 745741
JZ Capital Partners, Ltd.
JZCP is a London listed fund which invests in US and European micro-cap companies and US real estate. Its objective is to achieve an overall return comprised of a current yield and capital appreciation. JZCP receives investment advice from Jordan/Zalaznick Advisers, Inc. (“JZAI”) which is led by David Zalaznick and Jay Jordan. They have worked together for 30 years and are supported by teams of investment professionals in New York, Chicago, London and Madrid. JZAI’s experts work with the existing management of micro-cap companies to help build better businesses, create value and deliver strong returns for investors. JZCP also invests in mezzanine loans, first and second lien investments and other publicly traded securities. For more information please visit www.jzcp.com.